The Dearth of Representation in FDA Approved Drug Trials
Ibilibor, C.; Armbruster, S.; Parker, R.; Yu, J.-R.; Barros, A.
Show abstract
The generalizability of data derived from randomized controlled trials is of paramount importance given their utility in the Food & Drug Administration (FDA) drug approval process. An essential part of this process is the inclusion of reliably reported gender, race and ethnicity data in trials that lead to FDA drug approval. Despite previous mandates by the FDA and Clinicaltrials.gov, gender and race-specific data remains under reported. We reviewed 100 most recently approved FDA medications, and abstracted the clinical trial data from Clinicaltrials.gov that supported their approval. We then compared these FDA approved trials to non-FDA approved trials from the same year and of similar size. We found that 40% of the FDA trials were missing race/ethnicity information, while 24% of these trials did not include gender information. We demonstrate that there remains a significant amount of missing gender and racial/ethnic data in trials that lead to FDA-approved medications.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- How Informative Were Early SARS-CoV-2 Treatment and Prevention Trials? A longitudinal cohort analysis of trials registered on clinicaltrials.gov 94%
- Analysis of clinical trial registry entry histories using the novel R package cthist 93%
- Application of observational research methods to real-world studies for rare disease drugs: a scoping review protocol 93%
Similar papers in this journal
- Reporting of Retrospective Registration in Clinical Trial Publications 94%
- Comparison of preprints and final journal publications from COVID-19 Studies: Discrepancies in results reporting and spin in interpretation 93%
- An Analysis of Controlled Human Infection Studies Registered on ClinicalTrials.gov 93%
Similar papers in this journal
- Evidence Supporting EMA Drug Approvals (2020-2023): A Cross-Sectional Study of Trial Design and Outcomes 94%
- Design and implementation of the multi-arm, multi-stage Therapeutics for Inpatients with COVID-19 (TICO) platform master protocol: An Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative 93%
- Data management in substance use disorder treatment research: Implications from data harmonization of National Institute on Drug Abuse-funded randomized controlled trials 90%
Similar papers in this journal
- Results reporting for clinical trials led by medical universities and university hospitals in the Nordic countries was often missing or delayed 94%
- The use of the Registered Reports format for publication of randomized clinical trials: a cross-sectional study 94%
- Strength of Statistical Evidence for the Efficacy of Cancer Drugs: A Bayesian Re-Analysis of Trials Supporting FDA Approval 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.